AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32554740
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) using a limited sampling strategy (t=0 and t=5 hours)
Trial: 38267496
Drug: Complement inhibitors
RxNorm normalized name: Complement inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complement inhibitors
Trial: 32555070
Drug: Mindful movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful movement treatment (8-week program, 2 classes per week for 60 minutes)
Trial: 32555070
Drug: Mindful movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful movement treatment
Trial: 32555630
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg (6-9 injections)
Trial: 32555630
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg (2-5 injections)
Trial: 32555630
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg (1 injection)
Trial: 32555630
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg (baseline VA <23 letters)
Trial: 32556281
Drug: IV pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV pembrolizumab 10 mg/kg every 2 weeks for up to 2 years or until confirmed progression or unacceptable toxicity
Trial: 32556682
Drug: High-dose stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose stereotactic body radiation therapy (SBRT)
Trial: 32556731
Drug: Cytoreduction, gastrectomy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreduction, gastrectomy, and HIPEC with 30 mg mitomycin C and 200 mg cisplatin
Trial: 32556819
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy during EGD
Trial: 32556819
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy during colonoscopy
Trial: 32556819
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic therapy during EGD
Trial: 32556819
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic therapy during colonoscopy
Trial: 32557168
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injections (2.0 mg) administered using a fixed dosing regimen during the first year and a treat-and-extend treatment regimen during the second year.
Trial: 32557382
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg weekly for up to 148 weeks
Trial: 32557394
Drug: Tiotropium/Olodaterol fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium/Olodaterol fixed-dose combination (FDC) administered for 6 weeks
Trial: 32557394
Drug: Tiotropium/Olodaterol fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium/Olodaterol fixed-dose combination (FDC)
Trial: 32557834
Drug: Immunomodulatory treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory treatment
Trial: 32557976
Drug: Matched targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched targeted agents for patients with druggable alterations
Trial: 32558402
Drug: Open-label ganaxolone
RxNorm normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label ganaxolone (225 mg twice daily, increased to 450 mg twice daily if tolerated) administered for 8 weeks
Trial: 32558407
Drug: Escitalopram monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram monotherapy (10-20 mg daily for 8 weeks)
Trial: 32558407
Drug: Aripiprazole augmentation
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole augmentation (2-10 mg daily for 8 weeks)
Trial: 32558897
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with irradiated, CpG-activated tumor cells followed by reinfusion of vaccine-primed lymphocytes after ASCT
Trial: 32559194
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of omics and clinical variables
Trial: 32561087
Drug: Preoperative portal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative portal embolization (PVE) plus administration of CD133 + cells mobilized from peripheral blood with G-CSF
Trial: 32561664
Drug: Tislelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab (200 mg i.v. Q3W) plus chemotherapy (cisplatin and fluorouracil for ESCC; oxaliplatin and capecitabine for G/GEJ)
Trial: 32562609
Drug: EUS assessment
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EUS assessment and endoscopic pancreatic function tests (ePFTs) with intravenous secretin 0.2 μg/kg
Trial: 32563721
Drug: First anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First anti-TNF therapy
Trial: 32563721
Drug: Non-biologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-biologic therapy augmentation
Trial: 32563721
Drug: Anti-TNF discontinuation
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF discontinuation
Trial: 32564277
Drug: Epacadostat 25
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat 25 mg or 100 mg BID
Trial: 32564277
Drug: Epacadostat 100
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat 100 mg BID with pembrolizumab 200 mg every 3 weeks
Trial: 32564277
Drug: Epacadostat 25
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat 25 mg BID with pembrolizumab 200 mg every 3 weeks
Trial: 32564277
Drug: Overall treatment-related
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment-related adverse events
Trial: 32564301
Drug: Vixotrigine 150
RxNorm normalized name: Vixotrigine
DrugBank: Vixotrigine (DB11706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vixotrigine 150 mg three times daily for 6 days and once on day 7
Trial: 32565475
Drug: Dialectical Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behaviour Therapy (DBT) skill-infused college course, consisting of 15 weekly 2.5-hour lessons, weekly homework assignments, and a final examination.
Trial: 32567415
Drug: Dehydrated human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dehydrated human amniotic membrane allograft (DAMA) with comprehensive care, applied weekly for 4 months
Trial: 32567817
Drug: Osimertinib (80-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80-mg oral dose) in patients with severe renal impairment (SRI)
Trial: 32567817
Drug: Osimertinib (80-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80-mg oral dose) in patients with normal renal function (NRF)
Trial: 32568632
Drug: Biochemical nonadherence
RxNorm normalized name: PAD,NONADHERENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biochemical nonadherence to tamoxifen (serum level < 60 ng/mL)
Trial: 32568632
Drug: Self-reported adherence
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported adherence to tamoxifen therapy
Trial: 33722961
Drug: Neuroform Atlas
RxNorm normalized name: LACTIC ACID 0.58 g in 100 g TOPICAL LIQUID [Atlas Prep Activator]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroform Atlas Stent System with adjunctive coiling
Trial: 32568958
Drug: Intravitreal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal and sub-Tenon's injections of bone marrow-derived stem cells
Trial: 32571613
Drug: High-normal inflammation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-normal inflammation marker concentrations (hsCRP >0.57-9.98 mg/L, mid/upper tertile)
Trial: 32572470
Drug: DENV-1-LVHC strain
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DENV-1-LVHC strain 45AZ5 (low-dose group: 0.5 mL of 6.5 × 103 PFU/mL)
Trial: 32572470
Drug: DENV-1-LVHC strain
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DENV-1-LVHC strain 45AZ5 (mid-dose group: 0.5 mL of 6.5 × 104 PFU/mL)
Trial: 32572470
Drug: DENV-1-LVHC strain
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DENV-1-LVHC strain 45AZ5 (both doses)
Trial: 32572849
Drug: ePIPAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePIPAC with oxaliplatin (92 mg/m2)
Trial: 32574101
Drug: Seven-valent pneumococcal
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven-valent pneumococcal conjugate vaccine (PCV7)
Trial: 32574101
Drug: Pneumococcal non-typeable
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal non-typeable vaccine
Trial: 32575130
Drug: G-POEM (Gastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-POEM (Gastric Peroral Endoscopic Myotomy)
Trial: 32576633
Drug: Clinical score
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical score (0 to 12 points) based on 6 variables: seizure(s) at presentation, known thrombophilia, oral contraception, duration of symptoms >6 days, worst headache ever, focal neurologic deficit at presentation.
Trial: 32576633
Drug: D-dimers >675
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimers >675 μg/L (best cutoff)
Trial: 32576633
Drug: D-dimers >500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimers >500 μg/L
Trial: 32576633
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical score and D-dimers >500 μg/L
Trial: 32578220
Drug: IVF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF therapy
Trial: 32578441
Drug: RIPK1 kinase
RxNorm normalized name: Kinase (enzyme-activating), uro-urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIPK1 kinase inhibitor (Nec-1)
Trial: 32578964
Drug: Sequential bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential bortezomib (BTZ) 1.3 mg/m² intravenously + temozolomide (TMZ) therapy
Trial: 32580249
Drug: Subsequent surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent surgical and nonsurgical therapies after primary treatment failure
Trial: 32580249
Drug: Vinblastine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine monotherapy
Trial: 32580249
Drug: First-line adjuvant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line adjuvant treatment
Trial: 32580597
Drug: Chimeric antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor-modified T cells
Trial: 32580757
Drug: Hyperuricemia (SUA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperuricemia (SUA > 7 mg/dL in males and > 6 mg/dL in females)
Trial: 32580757
Drug: Normouricemia (SUA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normouricemia (SUA ≤ 7 mg/dL in males and ≤ 6 mg/dL in females)
Trial: 32580982
Drug: Zero Childhood
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zero Childhood Cancer Personalised Medicine Program
Trial: 32580988
Drug: Septic cardiomyopathy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Septic cardiomyopathy assessment and comprehensive cardiovascular and molecular deep phenotyping including echocardiographic and electrocardiographic assessment, heart rate variability, body composition, mitochondrial oxygen metabolism, macrocirculation and microcirculation, endothelial barrier function, routine immunological, haematological and biochemical tests, serum metabolome and lipidome analyses, microbiome and epigenetic modifications of immune cells.
Trial: 32580987
Drug: Antibiotic exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic exposure in the first year of life
Trial: 32580987
Drug: Disruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disruption of the infant oral and intestinal microbiome
Trial: 32580987
Drug: Compositional overlap
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compositional overlap between maternal intestinal microbiome, breast milk microbiome, and infant oral and intestinal microbiome
Trial: 32581767
Drug: EAHE (Erinacine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAHE (Erinacine A-Enriched) mycelia capsules, 5 mg/g, three capsules per day for 49 weeks
Trial: 32581767
Drug: Placebo capsules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, identical in appearance to EAHE capsules, for 49 weeks
Trial: 32581961
Drug: Rhythmic Reading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythmic Reading Training (RRT) administered for 13 hours over 9 days
Trial: 32581961
Drug: Visual Hemisphere-Specific
RxNorm normalized name: Fluzone 2025 Southern Hemisphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual Hemisphere-Specific Stimulation (VHSS) + Action Video Game Training (AVG) administered for 13 hours over 9 days
Trial: 32582547
Drug: P10s-PADRE vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P10s-PADRE vaccine
Trial: 32583052
Drug: Alemtuzumab (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days)
Trial: 32583749
Drug: Drug-Coated Balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Coated Balloon Angioplasty
Trial: 32584051
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol self-administration (ivASA)
Trial: 32586767
Drug: Atezolizumab 15
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 15 mg/kg or 1200 mg intravenously every 3 weeks for 16 cycles or until loss of clinical benefit
Trial: 32586937
Drug: Mogamulizumab 1
RxNorm normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mogamulizumab 1 mg/kg plus Durvalumab 10 mg/kg
Trial: 32586937
Drug: Mogamulizumab 1
RxNorm normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mogamulizumab 1 mg/kg plus Tremelimumab 10 mg/kg
Trial: 32586937
Drug: Mogamulizumab in
RxNorm normalized name: mogamulizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mogamulizumab in combination with Durvalumab or Tremelimumab
Trial: 32588218
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (high intake of parenteral fluids)
Trial: 32588218
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (low intake of parenteral fluids)
Trial: 32589310
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 30 mg/day for 3 weeks, tapered off over 12 weeks
Trial: 32589738
Drug: Nevanimibe (ATR-101)
RxNorm normalized name: Nevanimibe
DrugBank: Nevanimibe (DB16254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevanimibe (ATR-101) at doses of 125, 250, 500, 750, 1000 mg twice daily for 2 weeks followed by a 2-week placebo washout.
Trial: 32590747
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg daily on days 1 to 21 of a 28-day cycle
Trial: 32591978
Drug: Peficitinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peficitinib (100 mg) administered twice daily from Day 3 to Day 9, coadministered with methotrexate on Day 8
Trial: 32591978
Drug: Methotrexate (15-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (15-25 mg)
Trial: 32593522
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of total polyphenols intake (319.9 mg/d)
Trial: 32594377
Drug: Candida antigen
RxNorm normalized name: Candida antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candida antigen immunotherapy
Trial: 32595770
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy (Norditropin®; Novo Nordisk) at a dosage of 0.469 mg/kg/week for 12 months (group A)
Trial: 32595770
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy (Norditropin®; Novo Nordisk) for 6 months after 6 months untreated (group B)
Trial: 32597029
Drug: Prophylactic rurioctocog
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic rurioctocog alfa pegol (fixed dose, twice-weekly or less frequent)
Trial: 32597029
Drug: Prophylactic rurioctocog
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic rurioctocog alfa pegol (fixed dose, twice-weekly)
Trial: 32597029
Drug: Prophylactic rurioctocog
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic rurioctocog alfa pegol (PK-tailored dose regimen)
Trial: 32597419
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care radiotherapy ± chemotherapy
Trial: 32598033
Drug: Statin medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin medication
Trial: 32598257
Drug: Selinexor 40
RxNorm normalized name: selinexor 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 40 mg plus mFOLFOX6
Trial: 32598257
Drug: Selinexor 20
RxNorm normalized name: selinexor 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 20 mg plus mFOLFOX6
Trial: 32600857
Drug: Multimodal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal intervention including fish oil intake (2g daily), dietary counselling, and unsupervised physical exercise twice weekly during the first three cycles of treatment
Trial: 32601169
Drug: Caspofungin standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin standard dosing
Trial: 32602006
Drug: Kidney dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney dysfunction upon admission (eGFR < 60 mL/min/1.73 m²)
Trial: 32602006
Drug: eGFR >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR > 60 mL/min/1.73 m²
Trial: 32604962
Drug: Abatacept +
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept + MTX with GC (≤10 mg/day)
Trial: 32604962
Drug: Adalimumab +
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab + MTX with GC (≤10 mg/day)
Trial: 32604962
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (abatacept and adalimumab)
Trial: 32605050
Drug: Hypo-fractionated stereotactic
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypo-fractionated stereotactic radiation (HFSRT; 6 Gy × 5) plus pembrolizumab (100 or 200 mg, every 3 weeks) and bevacizumab (10 mg/kg, every 2 weeks)
Trial: 32605888
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all MRI sequences
Trial: 32606066
Drug: Consensus-based recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consensus-based recommendations for perioperative medication safety tailored to country income level
Trial: 32606578
Drug: Ranibizumab 0.3
RxNorm normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.3 or 0.5 mg
Trial: 32606899
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (LICUS, 3MHz, 0.132W/cm, 18,720 Joules)